TAK | Takeda Pharmaceutical Company Limited Stock Overview

(Stock Exchange: NYSE)

Day's Range	13.93 - 14.10
52 Week Range	12.58 - 15.08
Beta	0.27
Implied Volatility	46.43%
IV Rank	43.96%
Day's Volume	1,391,727
Average Volume	1,735,238
Shares Outstanding	3,170,363,280
Market Cap	44,575,307,717
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2010-01-05

Valuation
Profitability
Growth
Health
P/E Ratio	32.70
Forward P/E Ratio	6.44
EPS	0.43
1YR Price Target	16.40
Dividend Yield	4.71%
Dividend Per Share	0.66
Dividend ExDate	2021-09-29
Dividend PayDate	2021-12-13
Employees	49,281
Country	Japan
Website	TAK

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

TAK's peers: BHC, VTRS, ELAN, ZTS, EBS, PBH, AMPH, DCPH, PCRX, COLL, SIGA, INVVY, ESPR, CTLT, EVO, EGRX, NBIX, PAHC, TEVA, HLN

*Chart delayed

Analyzing fundamentals for TAK we got that it has average fundamentals where Valuation is considered to be significantly undervalued, Profitability is unacceptably poor, Growth is exceptionally good and Health is very weak. For more detailed analysis please see TAK Fundamentals page.

Watching at TAK technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on TAK Technicals page.